Corcept Therapeutics (NASDAQ: CORT) reported Q4 GAAP EPS of $0.04, $0.03 better than the analyst estimate of $0.01. Revenue for the quarter came in at $23.8 million versus the consensus estimate of $23.46 million.

GUIDANCE:

Corcept Therapeutics sees FY2017 revenue of $115-125 million.

For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.